Is AGIOS PHARMACEUTICALS, INC. (AGIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.5% / 30% | 53.1% / 30% | 0.7% / 30% | 104.35% / 5% | ✗ NOT HALAL |
| DJIM | 2.5% / 33% | 53.1% / 33% | 0.7% / 33% | 104.35% / 5% | ✗ NOT HALAL |
| MSCI | 3.1% / 33% | 65.9% / 33% | 0.8% / 33% | 104.35% / 5% | ✗ NOT HALAL |
| S&P | 2.5% / 33% | 53.1% / 33% | 0.7% / 33% | 104.35% / 5% | ✗ NOT HALAL |
| FTSE | 3.1% / 33% | 65.9% / 33% | 0.8% / 50% | 104.35% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -608.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -30.2% | |
| Return on Assets (ROA) | -19.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$373M |
| Free Cash Flow | -$387M |
| Total Debt | $40M |
| Debt-to-Equity | 3.4 |
| Current Ratio | 11.5 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $29.95 |
| 50-Day MA | $28.28 |
| 200-Day MA | $33.81 |
| Avg Volume | 982K |
| Beta | 0.9 |
|
52-Week Range
$22.24
| |
About AGIOS PHARMACEUTICALS, INC. (AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AGIOS PHARMACEUTICALS, INC. (AGIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AGIOS PHARMACEUTICALS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AGIOS PHARMACEUTICALS, INC.'s debt ratio?
AGIOS PHARMACEUTICALS, INC.'s debt ratio is 2.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.1%.
What are AGIOS PHARMACEUTICALS, INC.'s key financial metrics?
AGIOS PHARMACEUTICALS, INC. has a market capitalization of $1.7B, and revenue of $54M. Return on equity stands at -30.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.